Shionogi Inc announced availabilty of Kapvay

Shionogi Inc., the U.S.-based group company of Shionogi & Co., Ltd., announced a true milestone as it marks the first commercial availability for the noncentral nervous system stimulant medication KAPVAY, an extended-release oral formulation of clonidine for Attention Deficit Hyperactivity Disorder (ADHD) in children and adolescents.

KAPVAY is the first and only FDA-approved ADHD treatment indicated for use as add-on therapy to stimulant medication, in addition to use as monotherapy.

Donald C. Manning, MD, PhD, Chief Medical Officer of Shionogi Inc said, Shionogi is extremely proud to bring KAPVAY? to market in the U.S. The extended-release version of clonidine hydrochloride found in KAPVAY? offers an exciting new treatment option for children and adolescents with ADHD who are not experiencing adequate symptom relief from stimulants alone.

ADHD affects more than 4.5 million children in the U.S., with at least 7 percent of U.S. school-aged children believed to suffer from the condition. Symptoms include difficulty in maintaining attention and focus and in controlling behavior, as well as hyperactivity/over-activity. While stimulant medications remain a first line treatment for ADHD, up to 30 percent of ADHD patients do not achieve an optimal response to stimulant monotherapy.